US2003138436A1PendingUtilityA1

Method of using a vaccine

37
Assignee: MALAGHAN INST OF MEDICAL RESPriority: Oct 5, 1998Filed: Nov 7, 2002Published: Jul 24, 2003
Est. expiryOct 5, 2018(expired)· nominal 20-yr term from priority
Inventors:Graham Le GrosCharles Richard William BeasleyJohn William HollowayKlaus Erb
A61K 2039/521A61K 2039/544A61K 39/04A61K 2039/52A61K 2039/57
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention is directed to methods of preventing or reducing the severity of asthma or the risk of development of same in an individual. The method relies on administration to the airways of the individual of an immunologically effective dose of a mycobacterium based vaccine. The mycobacteria are effective in inducing a Th1 type immune response in the individual.

Claims

exact text as granted — not AI-modified
1 . A method for reducing the severity of asthma and for reducing the risk of developing asthma comprising administering a vaccine consisting of an immunologically effective dose of Th1 type immune response inducing mycobacteria to the airways of individuals.  
     
     
         2 . The method of  claim 1  wherein the vaccine is administered to the respiratory tract.  
     
     
         3 . The method of  claim 1  wherein the vaccine consists of  Mycobacterium bovis  (Bacillus Calmette-Guerin [BCG]).  
     
     
         4 . The method of  claim 1  where the vaccine contains ≧2×10 5  colony forming units (CFUs) of mycobacteria.  
     
     
         5 . The method of  claim 1  where the vaccine contains ≧2×10 5  colony forming units (CFUs) of live mycobacteria.  
     
     
         6 . The method of  claim 1  where the vaccine contains ≧2×10 5  colony forming unit (CFU) equivalents of killed mycobacteria.  
     
     
         7 . The method of  claim 1  where the vaccine contains ≧2×10 5  colony forming unit (CFU) equivalents of mycobacterial cell wall components.  
     
     
         8 . The method of  claim 1  where the vaccine contains ≧2×10 5  colony forming unit (CFU) equivalents of mycobacterial cell membrane components.  
     
     
         9 . The method of  claim 1  where the vaccine contains ≧2×10 5  colony forming unit (CFU) equivalents of mycobacterial cell cytoplasm components.  
     
     
         10 . The method of  claim 1  where the vaccine contains ≧2×10 5  colony forming unit (CFU) equivalents of mycobacterial genetic material.  
     
     
         11 . The method of  claim 1  where the vaccine contains ≧2×10 5  colony forming unit (CFU) equivalents of mycobacterial secreted products.

Join the waitlist — get patent alerts

Track US2003138436A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.